Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol SLDB
- Company Solid Biosciences Inc.
- Price $5.82
- Changes Percentage -11.82
- Change -0.78
- Day Low $5.74
- Day High $6.59
- Year High $15.05
- Year Low $1.81
- Market Cap $224,624,064
- Price Avg 50 EMA (D) $7.76
- Price Avg 200 EMA (D) $8.67
- Exchange NASDAQ
- Volume 464,409
- Average Volume 260,117
- Open $6.5
- Previous Close $6.6
- EPS -3.29
- PE -1.77
- Earnings Announcement 2024-11-06 21:00:00
- Shares Outstanding $38,595,200
Company brief: SOLID BIOSCIENCES INC. (SLDB )
- Healthcare
- Biotechnology
- Mr. Alexander G. Cumbo
- https://www.solidbio.com
- US
- N/A
- 01-26-2018
- US83422E2046
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.